<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252199</url>
  </required_header>
  <id_info>
    <org_study_id>CTP_STX005/STX005EXT</org_study_id>
    <nct_id>NCT01252199</nct_id>
  </id_info>
  <brief_title>Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2</brief_title>
  <official_title>A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thallion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LFB Biotechnologies, SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thallion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of cαStx1 and cαStx2 administered
      concomitantly in children presenting early signs of Shiga Toxin-Producing Bacterial (STPB)
      Infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no etiological treatment of STPB-induced HUS. Ideally, such treatment
      would be started in the early phase of the infection and would protect against both types of
      toxins and all of their variants. The chimeric anti-Shiga toxins 1 (cαStx1) and 2 (cαStx2)
      antibodies are intended to be administered as a single infusion and provide simultaneous
      protection against the two Shiga toxins (Stx1 and Stx2) by decreasing the incidence and
      severity of Shiga toxin-mediated clinical events including bloody diarrhea/hemorrhagic
      colitis and Hemolytic Uremic Syndrome (HUS) and associated sequelae.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: Evaluation of number and type of adverse events and serious adverse events between arms and dosage cohorts</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of the safety and tolerability of two different intravenous dose levels of a combined cαStx1/cαStx2 preparation in separate groups of children presenting with Shiga Toxin-Producing Bacterial (STPB) infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Comparison of clinical event rates (Hemolytic Uremic Syndrome, Bloody Diarrhea) and associated sequelae between arms and dosage cohorts in children presenting with Shiga Toxin-Producing Bacterial (STPB) infection.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Shiga Toxin Producing Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>cαStx1/cαStx2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cαStx1/cαStx2</intervention_name>
    <description>cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care</description>
    <arm_group_label>cαStx1/cαStx2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered over 1 hour + standard of care</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Bloody diarrhea (by visual inspection) for no more than 36 hours prior to screening
             (signature of the informed consent).

          2. Detection of Shiga toxin (Stx1 and/or Stx2) in stool

        Exclusion Criteria:

          1. Laboratory findings compatible with development of at least two out of three following
             criteria that define Hemolytic Uremic Syndrome (HUS):

             Hemolytic Anemia: hematocrit &lt; 30% with evidence of hemolysis (as indicated by Lactate
             Dehydrogenase (LDH) above the upper limit of normal for age or the finding of
             schistocytes on peripheral smear); Thrombocytopenia: platelet count &lt;150 x 103/uL;
             Nephropathy: serum creatinine &gt; Upper Limit Normal (ULN) adjusted for age and gender.

          2. Bloody-diarrhea suspected not to be caused by Shiga Toxin-Producing Bacteria (STPB)
             but by other organisms or preexisting diseases.

          3. Family history of proven or suspected hereditary Hemolytic Uremic Syndrome (HUS) or
             thrombotic thrombocytopenic purpura (TTP).

          4. History of chronic/recurrent hemolytic anemia or thrombocytopenia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bahia Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parana</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shigamabs</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Shiga</keyword>
  <keyword>Toxin</keyword>
  <keyword>E.coli</keyword>
  <keyword>HUS</keyword>
  <keyword>Bloody</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Shiga Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

